- Details
- In this follow-up discussion, Badar Mian and E David Crawford delve deeper into the implications of clinical trials comparing transperineal (TP) and transrectal (TR) prostate biopsies. They address key issues such as antibiotic use, patient comfort, and sampling accuracy. Dr. Mian notes that many European centers still use antibiotics for TP biopsies, contrary to claims of antibiotic avoidance. Th...
|
- Details
- Badar Mian discusses randomized clinical trials comparing transperineal (TP) and transrectal (TR) prostate biopsy approaches. Despite previous beliefs favoring TP biopsies for lower infection rates and better cancer detection, three major trials (ProBE-PC, PREVENT, and PERFECT) show no significant differences in sepsis rates or cancer detection between the two methods. The studies reveal similar m...
|
- Details
- Louise Emmett discusses the novel copper-64 bisPSMA agent for prostate cancer imaging. She explains its unique features, including a 12-hour half-life and bifid peptide structure, which potentially offer improved imaging characteristics over existing PSMA agents. Dr. Emmett highlights early study results showing higher intensity uptake in cancer cells compared to gallium PSMA-11. The conversation...
|
- Details
- Neal Shore discusses a new 64Cu-SAR-bisPSMA PET diagnostic agent for prostate cancer imaging with Phillip Koo. Dr. Shore highlights the unique features of this compound, including its bivalent structure and longer half-life compared to existing PSMA PET agents. He explains how these characteristics allow for next-day imaging, potentially improving detection rates and clinical flexibility. Dr. Shor...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Scott Eggener advocates for reclassifying Grade Group 1 prostate cancer, arguing that it should no longer be called cancer. He concludes by stressing the importance of focusing on individual and population health in this discussion, encouraging a respectful and productive dialogue among various s...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Matthew Cooperberg addresses the controversial topic of reclassifying Grade Group 1 prostate cancer. He argues that what is currently labeled as low-grade prostate cancer is essentially a normal feature of male aging and questions whether it should be considered cancer at all. Dr. Cooperberg high...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Adam Kibel presents counterarguments to reclassifying Grade Group 1 prostate cancer as non-cancer. He acknowledges the low risk of harm in patients who undergo radical prostatectomy for Grade Group 1 cancer but emphasizes that some patients with initial Grade Group 1 biopsies eventually progress...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Laura Esserman discusses the importance of reclassifying certain cancers, focusing on the impact of terminology and the need for more precise classification methods. She highlights the problem of overdiagnosis in cancer screening, particularly for indolent cancers, and emphasizes the need for obj...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Gladell Paner discusses the feasibility of reclassifying Grade Group 1 (GG1) prostate cancer from a pathological perspective. He acknowledges the debate between histologic features of cancer and the lack of clinical symptoms or metastasis in GG1 cases. Dr. Paner concludes that accepting a borderl...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Theo van der Kwast argues against reclassifying Grade Group 1 prostate cancer, emphasizing the pathological definition of adenocarcinoma. He highlights the infiltrative and locally aggressive nature of these tumors, noting their potential for perineural invasion and extraprostatic extension. He a...
|
